These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527 [TBL] [Abstract][Full Text] [Related]
26. Biotherapies targeting T and B cells: from immune suppression to immune tolerance. Chatenoud L Curr Opin Pharmacol; 2015 Aug; 23():92-7. PubMed ID: 26099946 [TBL] [Abstract][Full Text] [Related]
27. The new immunosuppression: intervention at the dendritic cell-T-cell interface. Paterson AM; Yates SF; Nolan KF; Waldmann H Curr Drug Targets Immune Endocr Metabol Disord; 2005 Dec; 5(4):397-411. PubMed ID: 16375693 [TBL] [Abstract][Full Text] [Related]
28. The use of monoclonal antibodies to achieve immunological tolerance. Waldmann H; Cobbold S Trends Pharmacol Sci; 1993 May; 14(5):143-8. PubMed ID: 8212308 [TBL] [Abstract][Full Text] [Related]
29. The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Kishimoto K; Dong VM; Sayegh MH Curr Opin Urol; 2000 Mar; 10(2):57-62. PubMed ID: 10785843 [TBL] [Abstract][Full Text] [Related]
30. Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance. Kishimoto TK; Maldonado RA Front Immunol; 2018; 9():230. PubMed ID: 29515571 [TBL] [Abstract][Full Text] [Related]
31. Aspirin and immune system. Hussain M; Javeed A; Ashraf M; Zhao Y; Mukhtar MM; Rehman MU Int Immunopharmacol; 2012 Jan; 12(1):10-20. PubMed ID: 22172645 [TBL] [Abstract][Full Text] [Related]
32. Regulatory T-Cell Therapy in Transplantation and Severe Autoimmunity. Rossetti M; Spreafico R Crit Rev Immunol; 2015; 35(6):479-503. PubMed ID: 27279045 [TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive monoclonal antibodies: current and next generation. Focosi D; Maggi F; Pistello M; Boggi U; Scatena F Clin Microbiol Infect; 2011 Dec; 17(12):1759-68. PubMed ID: 21995285 [TBL] [Abstract][Full Text] [Related]
35. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. Li L; Boussiotis VA J Mol Med (Berl); 2006 Nov; 84(11):887-99. PubMed ID: 16972086 [TBL] [Abstract][Full Text] [Related]
37. New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation? You S; Chatenoud L Curr Opin Organ Transplant; 2010 Dec; 15(6):720-4. PubMed ID: 20881491 [TBL] [Abstract][Full Text] [Related]
38. The role of tunable activation thresholds in the dynamics of autoimmunity. Blyuss KB; Nicholson LB J Theor Biol; 2012 Sep; 308():45-55. PubMed ID: 22659039 [TBL] [Abstract][Full Text] [Related]